title: Quantitative evaluation of DNMT3B promoter methylation in breast cancer patients using differential high resolution melting analysis.
abstract: DNA methylation plays an important role in carcinogenesis through epigenetic silencing of tumor suppressor genes. Aberrant methylation usually results from changes in the activity of DNA methyltransferases (DNMTs). Some studies show that the overexpression of the DNMTs may lead to aberrant methylation of tumor suppressor genes. Also the overexpression of DNMTs may be related to methylation status of their genes. Due to limited number of studies on DNMT3B promoter methylation, this study was performed to quantitatively measure the methylation level of DNMT3B gene in archival formalin fixed paraffin embedded (FFPE) tissues from breast cancer patients. Using differential high resolution melting analysis (D-HRMA) technology, the methylation level of DNMT3B gene promoter was quantified in 98 breast cancer FFPE tissues and also 10 fresh frozen normal tissue samples. Statistical analyses used for analyzing the correlation between the methylation and clinical variables. All the normal samples were found to be methylated at the DNMT3B promoter (the average methylation level 3.34%). Patients were identified as hypo-methylated (mean methylation level 0.8%), methylated (mean methylation level 2.48%) and hyper-methylated (mean methylation level 10.5%). Statistical analysis showed a significant correlation between the methylation status and the sample type, cancer type and tumor size. Also the methylation level was significantly associated with histologic grade. It is concluded that quantification of DNMT3B promoter methylation might be used as a reliable and sensitive diagnostic and prognostic tool in breast cancer. Also D-HRMA is demonstrated as a rapid and cost effective method for quantitative evaluation of promoter methylation.
authors.affiliation: Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Sciences Research Center School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
authors.forename: M
authors.initials: M
authors.lastname: Naghitorabi
authors.forename: J
authors.initials: J
authors.lastname: Mohammadi Asl
authors.forename: H
authors.initials: H
authors.lastname: Mir Mohammad Sadeghi
authors.forename: M
authors.initials: M
authors.lastname: Rabbani
authors.forename: A
authors.initials: A
authors.lastname: Jafarian-Dehkordi
authors.forename: Haghjooye S
authors.initials: HS
authors.lastname: Javanmard
keywords: Breast cancer; DNA methylation; DNMT3B; FFPE; High resolution melting analysis
references.citation: PLoS One. 2011 Feb 10;6(2):e16831
references.pmid: 21347319
references.citation: Cancer Lett. 2006 Feb 28;233(2):271-8
references.pmid: 15885882
references.citation: Oncogene. 2006 Apr 27;25(18):2636-45
references.pmid: 16532039
references.citation: Mol Cell Biol. 2007 Dec;27(24):8748-59
references.pmid: 17938196
references.citation: J Mol Diagn. 2009 Mar;11(2):102-8
references.pmid: 19179456
references.citation: Diagn Pathol. 2012 Jan 20;7:8
references.pmid: 22264301
references.citation: J Clin Endocrinol Metab. 2008 Sep;93(9):3610-7
references.pmid: 18544619
references.citation: Nucleic Acids Res. 2009 Jul;37(12):e86
references.pmid: 19454604
references.citation: Clin Chim Acta. 2010 Jul 4;411(13-14):940-6
references.pmid: 20227403
references.citation: Lung Cancer. 2007 Feb;55(2):205-13
references.pmid: 17140695
references.citation: Curr Genomics. 2009 Aug;10(5):336-52
references.pmid: 20119531
references.citation: Nucleic Acids Res. 2009 May;37(8):2658-71
references.pmid: 19270063
references.citation: J Neurooncol. 2011 Sep;104(2):483-94
references.pmid: 21229291
references.citation: Clin Cancer Res. 2003 Oct 1;9(12):4415-22
references.pmid: 14555514
references.citation: Cancer Lett. 2005 Aug 8;226(1):77-84
references.pmid: 16004934
references.citation: Cancer Cell Int. 2008 Sep 17;8:13
references.pmid: 18798999